[Intravenous immunoglobulins and autoimmune thrombopenic purpura].
OBJECTIVE
To determine the usefulness of intravenous immunoglobulin in the treatment of autoimmune thrombocytopenic purpura (AITP).


RESULTS
IVIg infusion is an important agent in managing AITP because most patients experienced a rapid increased platelet count. Its precise place in the management of these patients is however controversial, particularly on account of its high cost and transient effect. It is indicated in the severe form of the disease or before surgery in corticoresistant patients.


CONCLUSIONS
Prospective studied are mandatory to compare the efficacy of IVIg and high dose corticosteroids in this indication.
Godeau
B
B
Service de médecine interne I, Hôpital Henri-Mondor, Créteil, France.
Bierling
P
P
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016527:Drug Costs; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000276:immunology / Q000628:therapy*; D013256:Steroids; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D013256:Steroids